A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Salk scientists identify protein BCL6 as a key regulator of muscle maintenance in mice; BCL6-enhancing therapies may prevent ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.